Study #2017-0228
Randomized Phase II trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
MD Anderson Study Status
Not Accepting
Treatment Agent
Osimertinib
Description
This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving osimertinib, surgery, and radiation therapy may work better at treating non-small cell lung cancer with EGFR mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Study phase:
Phase II
Physician name:
Saumil Gandhi
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.